Key result
The use of B-type natriuretic peptide testing in patients presenting with dyspnea improves evaluation and management, and is both cost-effective and cost-saving.
Why the study?
Does the use of B-type natriuretic peptide improve evaluation and management and provide cost savings in patients presenting with dyspnea?
Does the use of B-type natriuretic peptide improve evaluation and management and provide cost savings in patients presenting with dyspnea?
The use of B-type natriuretic peptide in patients presenting with dyspnea improves clinical management and is cost saving.
Answers are grounded in this paper and cite their sources.
Supports BNP testing for dyspnea evaluation and cost savings; leaves open need for prospective trials before practice change.
In Brief B-type natriuretic peptide is a quantitative marker of cardiac stress and heart failure that summarizes the hemodynamic impact of the presence and extent of various cardiac disease processes, including systolic left ventricular dysfunction, left ventricular diastolic dysfunction, valvular dysfunction, and right ventricular dysfunction. Both observational and randomized controlled studies have unequivocally demonstrated that the additional use of this diagnostic test improves the evaluation and management of patients presenting with dyspnea. Moreover, the use of B-type natriuretic peptide in this setting is not only cost-effective, but cost saving. B-type natriuretic peptide is a quantitative marker of cardiac stress and heart failure that summarizes the hemodynamic impact of the presence and extent of various cardiac disease processes. Both observational and randomized controlled studies have unequivocally demonstrated that the additional use of this diagnostic test improves the evaluation and management of patients presenting with dyspnea, and is both cost-effective and cost saving.
No takes yet. Share an insight, caveat, or question.
Christian Mueller (2009) conducted a review in Dyspnea. B-type natriuretic peptide testing was evaluated. The use of B-type natriuretic peptide testing in patients presenting with dyspnea improves evaluation and management, and is both cost-effective and cost-saving.
Synapse has enriched 10 related papers. Consider them for comparative context: